Table 1 Demographics and clinical characteristics at baseline
| Â | HLX01 (n = 183) | Placebo (n = 92) |
|---|---|---|
Age, years, mean (SD) | 49.1 (11.8) | 47.9 (11.0) |
Female, n (%) | 153 (83.6) | 80 (87.0) |
Chinese, n (%) | 183 (100) | 92 (100) |
BMI, kg/m2, mean (SD) | 22.7 (3.0) | 22.2 (3.2) |
Duration of disease, months, mean (SD) | 88.4 (87.7) | 75.5 (91.5) |
RF positive, n (%) | 167 (91.3) | 86 (93.5) |
Anti-CCP antibody positive, n (%) | 175 (95.6) | 81 (88.0) |
Anti-CCP antibody negative, n (%) | 7 (3.8) | 9 (9.8) |
SJC, mean (SD) | 11.8 (5.9) | 11.4 (7.3) |
TJC, mean (SD) | 20.9 (13.1) | 19.5 (12.7) |
CRP, mg/l, mean (SD) | 16.9 (21.0) | 22.2 (27.6) |
ESR, mm/h, mean (SD) | 39.2 (24.6) | 43.4 (28.1) |
DAS28-CRP, mean (SD) | 5.5 (0.9) | 5.4 (1.0) |
DAS28-ESR, mean (SD) | 6.1 (1.1) | 6.1 (1.1) |
HAQ-DI score, mean (SD) | 1.4 (0.7) | 1.5 (0.7) |
PtAAP-VAS score, mean (SD) | 60.5 (21.3) | 58.2 (21.5) |